A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

Although the company lowered its full-year outlook for adjusted earnings per share to between $8.82 and $8.97 from between $8.88 and $9.03, that was only because the new guidance included an expected ...

Merck lowered its full-year profit guidance and said tariffs would mean an extra $200 million in costs this year. The stock ...

Merck (MRK) stock trades flat as the company lowers earnings outlook amid tariff impact, even as its Q1 2025 results beat ...